“Increased medical and recreational storefront dispensary counts are associated with reduced opioid related mortality rates during the study period. These associations appear particularly strong for deaths related to synthetic opioids such as fentanyl….
In testimony before Congress last week, by DEA acting administrator Robert Patterson opined that the medicalization of cannabis is exacerbating opioid abuse. But when prompted to provide evidence in support of the agency’s position, he acknowledged that he could not.
Trauma patients who test positive for marijuana upon their admission to the intensive care unit are less likely to die during hospitalization than are age-matched controls, according to data published online ahead of print in The Journal of Trauma and Acute Care Surgery. Researchers concluded: “Patients with a positive marijuana screen had a lower mortality rate (5.3 percent versus 8.9 percent) compared to patients with a negative marijuana screen.”
[Editor’s note: This post is excerpted from this week’s forthcoming NORML weekly media advisory. To have NORML’s news alerts and legislative advisories delivered straight to your in-box, sign up here.] The use of cannabis is associated with lower mortality risk in patients with schizophrenia and related psychotic disorders, according to a forthcoming study to be published in the Journal of Psychiatric Research. (Read the abstract of the study online here.) An international team of investigators from the University of Maryland School of Medicine and Inje University in South Korea assessed […]